Peptide research 2026 in one sentence: peptides finally became pills. Between December 2025 and July 2026, the FDA approved three oral peptide drugs: Wegovy tablets, icotrokinra (Icotyde) and enlicitide (Lipfendra).[1][4][6] Meanwhile retatrutide produced 25.0% average weight loss in a phase 3 trial.[9] There were real setbacks too, most notably semaglutide’s failure in two large Alzheimer’s trials.[12]
We verified each item against FDA records, labels or peer-reviewed papers. New to peptides? Start at the peptide basics hub.
FDA approvals, August 2025 to October 2026
| Date | Drug | What it is | Use |
|---|---|---|---|
| August 2025 | Semaglutide (Wegovy) | Weekly GLP-1 injection | New indication: MASH liver disease with moderate to advanced fibrosis[17] |
| September 19, 2025 | Elamipretide (Forzinity) | Mitochondria-targeting peptide | Barth syndrome, accelerated approval[3] |
| December 22, 2025 | Semaglutide tablets (Wegovy) | Oral GLP-1 peptide with SNAC | Weight management and heart risk[1][17] |
| March 2026 | Icotrokinra (Icotyde) | Oral 13-amino-acid IL-23 receptor blocker | Plaque psoriasis[4] |
| July 2026 | Enlicitide (Lipfendra) | Oral macrocyclic PCSK9 blocker | High LDL cholesterol[6] |
Orforglipron (Foundayo), approved April 1, 2026, is a small-molecule GLP-1 pill, not a peptide. See our orforglipron profile and the full FDA-approved peptides list.
Why these approvals matter
Until late 2025, Rybelsus and oral octreotide were rare exceptions to the rule that peptide drugs are injected. The new approvals show three separate routes to a pill:
- An absorption enhancer at a higher dose. Wegovy tablets use SNAC with 25 mg of semaglutide daily.[17]
- A small, stable peptide. Icotrokinra is only 13 amino acids long and is taken once daily on an empty stomach.[4]
- A ring-shaped peptide plus an enhancer. Enlicitide combines a macrocyclic structure with sodium caprate and reaches about 1% bioavailability.[6]
Each targets a condition that already had injectable treatments, such as GLP-1 shots, IL-23 antibodies and PCSK9 antibodies. The question for patients is convenience and access, not a brand-new mechanism.
Elamipretide is different. It is a small peptide that targets mitochondria and treats Barth syndrome, a rare inherited disease. It received accelerated approval, which means confirmatory evidence of clinical benefit is still required.[3] Our SS-31 (elamipretide) profile has the details.
Key trial results
Oral semaglutide 25 mg (OASIS 4). 307 adults; 13.6% weight loss at 64 weeks versus 2.2% on placebo.[2] The basis for Wegovy tablets. How the pill gets absorbed is explained in oral peptide delivery.
Icotrokinra (ICONIC-LEAD). 684 adults and adolescents; 65% reached clear or almost clear skin at week 16 versus 8% on placebo.[5]
Enlicitide (CORALreef Lipids). 2,909 people at high heart risk; LDL cholesterol fell 57.1% at 24 weeks versus a 3.0% rise on placebo.[7]
Semaglutide for MASH (ESSENCE). 800 patients analyzed; steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide versus 34.3% on placebo.[8]
Retatrutide (TRIUMPH-1). 2,339 adults with obesity; average weight change at 80 weeks was −17.6%, −23.7% and −25.0% on 4, 9 and 12 mg, versus −3.9% on placebo. Knee pain and sleep apnea also improved in subgroups.[9] See our retatrutide profile.
Heart outcomes. In SURPASS-CVOT, tirzepatide was noninferior to dulaglutide for major cardiovascular events.[10] In SOUL, oral semaglutide lowered major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease.[11] More in GLP-1 heart outcomes.
The big setback: Alzheimer’s
The EVOKE and EVOKE+ trials tested oral semaglutide 14 mg in 3,808 people with early Alzheimer’s, after encouraging signals from animal and health-record studies. After 104 weeks, decline on the main dementia rating scale was about the same as placebo, and both trials were discontinued.[12] Details are in GLP-1 drugs for Alzheimer’s and Parkinson’s. The result is a reminder that early signals need confirmation in randomized trials; see animal vs human peptide studies for why.
Lab and genetics highlights
- Genes and GLP-1 response. A study of 27,885 GLP-1 users linked a GLP1R variant to about 0.76 kg extra weight loss per copy, and GLP1R and GIPR variants to nausea.[13] See personalized peptide therapy.
- AI-found antibiotics. Deep learning flagged 12,623 candidate antimicrobial peptides in archaea. Of 80 synthesized, 93% were active in the lab, and one worked in mice.[14] See AI-designed peptides.
What’s established vs preliminary
Established:
- Absorption enhancers and ring-shaped designs can make once-daily peptide pills work.[1][6]
- Triple-hormone agonism (retatrutide) produces larger weight loss than placebo in phase 3.[9]
- Oral semaglutide doesn’t slow early Alzheimer’s.[12]
Preliminary:
- Whether enlicitide lowers heart attacks and strokes; outcome data aren’t yet in.
- Whether retatrutide outperforms tirzepatide head to head.
- Gene-guided GLP-1 prescribing and AI-designed peptide drugs.
Limitations
- Several results are from single trials funded by the maker.
- Weight-loss results differ in how dropouts are counted, so cross-trial comparisons mislead. TRIUMPH-1 counted everyone randomized, while some company announcements report only people who stayed on treatment, which gives larger numbers.
- Popular wellness peptides, such as BPC-157, saw regulatory news but no large human trials. In 2026, FDA removed a group of peptides from its Category 2 list of compounding ingredients with significant safety risks after their nominations were withdrawn.[18] That changes compounding rules, not the evidence on whether they work. See FDA peptide ban 2026.
What’s next
- TRIUMPH-5: retatrutide versus tirzepatide in about 800 adults; primary completion estimated November 2026.[16]
- Retatrutide filing: Lilly said it plans to submit to the FDA in the first quarter of 2027.[15]
- Our method for judging new headlines is in how to read peptide research, and the classics are in most-cited peptide studies.
Questions to discuss with a clinician
- Is one of the new oral options a better fit for me than an injection?
- Does a new indication, like MASH, apply to my situation and insurance?
- Should I wait for head-to-head data before switching drugs?
- Are there trials of newer peptides I could join?
